Ambry Hits Myriad With Antitrust Claim In Gene Test IP Row
Ambry Genetics Corp. claimed Monday that Myriad Genetics Inc. has violated antitrust law and is trying to monopolize the market for breast cancer gene tests by filing a patent suit over...To view the full article, register now.
Already a subscriber? Click here to view full article